Last updated: September 8, 2026
GONAL-F RFF REDIJECT is a recombinant follitropin alfa product marketed in the United States by EMD Serono, a subsidiary of Merck KGaA. Its commercial position rests on established physician use, a prefilled multidose injection device, and demand from assisted reproductive technology and ovulation-induction procedures. Merck does not publicly report standalone GONAL-F RFF REDIJECT revenue, so the product’s financial trajectory must be assessed through Merck’s fertility portfolio, reproductive-health market trends, competitive products, pricing, and market-access conditions.
The principal risks are pricing pressure, fertility-treatment benefit restrictions, competition from follitropin beta and human menopausal gonadotropin products, and potential future biosimilar entry. The principal protections are brand familiarity, clinical switching costs, device convenience, manufacturing complexity, and the regulatory burden associated with follow-on biologics.
What is GONAL-F RFF REDIJECT and how is it used?
GONAL-F RFF REDIJECT contains follitropin alfa, a recombinant form of follicle-stimulating hormone. The product is used in controlled ovarian stimulation for patients undergoing assisted reproductive technology and for ovulation induction in selected patients with ovulatory dysfunction.
The RFF REDIJECT presentation is a prefilled, multidose injection pen. Available strengths have included 300 IU, 450 IU, and 900 IU presentations, subject to the current U.S. label and commercial availability. The device allows patients to administer individualized daily doses during ovarian stimulation.
GONAL-F RFF REDIJECT commercial attributes
| Attribute |
Assessment |
| Active ingredient |
Recombinant follitropin alfa |
| Product class |
Gonadotropin, recombinant FSH |
| Primary U.S. marketer |
EMD Serono, Inc. |
| Parent company |
Merck KGaA |
| Main uses |
Controlled ovarian stimulation and ovulation induction |
| Dosage form |
Prefilled multidose injection pen |
| Principal competitors |
Follistim AQ, Menopur, other gonadotropin products |
| Regulatory category |
Biologic |
| Standalone product revenue |
Not publicly disclosed |
| Core commercial advantage |
Brand recognition, fertility-clinic adoption, and pen delivery system |
FDA labeling identifies GONAL-F as a recombinant FSH product with dosing individualized to ovarian response and treatment protocol (U.S. Food and Drug Administration [FDA], 2023).
How large is the market for recombinant FSH and fertility drugs?
The addressable market is driven by the number of assisted reproductive technology cycles, age-related infertility, delayed childbearing, access to fertility benefits, and the growth of employer-sponsored fertility coverage. Demand is concentrated in high-income markets because treatment frequently requires substantial out-of-pocket payment.
Recombinant FSH products compete within a broader ovarian-stimulation market that includes:
- Follitropin alfa products such as GONAL-F.
- Follitropin beta products such as Follistim AQ.
- Urinary-derived human menopausal gonadotropin products such as Menopur.
- Long-acting FSH products, including corifollitropin alfa in markets where available.
- Biosimilar or follow-on follitropin products, particularly in Europe.
Clinical selection is influenced by physician familiarity, prior-cycle response, clinic protocols, drug availability, payer coverage, and patient preference for injection devices. Products are often used in combination with gonadotropin-releasing hormone antagonists, trigger agents, progesterone, and other fertility medicines.
Key market drivers
The strongest positive drivers are higher utilization of IVF, expanded employer fertility benefits, increased fertility preservation, and greater treatment access among older patients. The strongest negative drivers are reimbursement limits, treatment discontinuation after unsuccessful cycles, inflation in medication costs, and competition among specialty pharmacies and fertility clinics.
Fertility treatment is also sensitive to economic conditions. Patients paying cash may defer treatment when household budgets tighten. Employer coverage can expand volume, but negotiated formularies may reduce manufacturer net pricing.
What is the financial trajectory of GONAL-F RFF REDIJECT?
Merck KGaA does not provide a separate GONAL-F RFF REDIJECT revenue line in its public annual reporting. The product is included within the company’s Healthcare business and fertility-related activities. This prevents a reliable calculation of product-specific revenue, operating margin, or year-over-year growth from public filings alone.
Financial assessment
| Financial factor |
Directional impact |
| IVF and fertility-cycle growth |
Positive |
| Increased employer fertility coverage |
Positive |
| Mature-brand status |
Limits high-growth potential |
| Pen-based convenience |
Supports retention and premium positioning |
| Competitor gonadotropins |
Negative |
| Payer and specialty-pharmacy rebates |
Negative for net price |
| European biosimilar competition |
Negative outside the United States |
| U.S. biosimilar entry |
Future downside risk |
| Product-level disclosure |
Limited, reducing valuation precision |
Merck’s reporting provides corporate and business-sector performance, but it does not isolate GONAL-F revenue. Any investment model that assigns a precise sales trajectory to GONAL-F RFF REDIJECT without nonpublic prescription, unit, or net-price data is speculative.
The most defensible financial conclusion is that GONAL-F is a mature fertility franchise asset with recurring demand and established clinical adoption, rather than a recently launched growth product. Revenue performance is likely to depend more on market expansion, pricing, formulary placement, and market share retention than on large increases in treatment penetration.
How does GONAL-F compare with Follistim AQ and Menopur?
GONAL-F RFF REDIJECT competes primarily on product familiarity, recombinant manufacturing, dose flexibility, and delivery-device convenience.
| Product |
Active ingredient or class |
Manufacturer |
Competitive position |
| GONAL-F RFF REDIJECT |
Follitropin alfa |
EMD Serono/Merck KGaA |
Established recombinant FSH brand with pen delivery |
| Follistim AQ Cartridge |
Follitropin beta |
Organon |
Direct recombinant FSH competitor |
| Menopur |
Menotropins, including FSH and LH activity |
Ferring |
Urinary-derived gonadotropin with broad fertility-clinic use |
| Bemfola |
Follitropin alfa biosimilar |
Gedeon Richter and partners |
European biosimilar competitor |
| Rekovelle |
Follitropin delta |
Ferring |
Long-acting or differentiated recombinant FSH option in selected markets |
The clinical distinction between follitropin alfa and follitropin beta may not by itself determine prescribing. Clinic purchasing, payer rules, prior authorization, inventory, and device preference can be more important commercial variables.
Menopur competes differently because it provides both FSH and LH activity. That positioning can support use in protocols where clinicians prefer a urinary-derived gonadotropin rather than a recombinant FSH-only product.
What patents protect GONAL-F RFF REDIJECT?
The principal intellectual-property layers are likely to include historic composition and recombinant-production patents, manufacturing know-how, formulation protection, device patents, packaging rights, and method-of-use claims. The commercial importance of older core patents is reduced when their terms expire, while device and manufacturing rights can remain relevant to product substitution.
Because GONAL-F is a therapeutic biologic, its U.S. regulatory framework differs from that of a conventional small-molecule drug. The biologic reference product is generally assessed under the Public Health Service Act and the 351(k) biosimilar pathway, rather than through an abbreviated new drug application and routine Paragraph IV certification.
A definitive current patent-expiration schedule for the marketed RFF REDIJECT presentation cannot be established from Merck’s public financial reports or the FDA prescribing information. Patent rights can differ by formulation, device, manufacturing process, and jurisdiction. The absence of a publicly reported product-specific patent table also limits a reliable estimate of remaining enforceable exclusivity.
What formulations are protected by GONAL-F-related patents?
Potentially relevant protection categories include:
- Recombinant follitropin alfa production methods.
- Purification and glycosylation-control processes.
- Stabilized liquid formulations.
- Multidose pen cartridges.
- Dose-delivery mechanisms and pen components.
- Manufacturing controls and analytical methods.
- Treatment protocols involving ovarian stimulation.
The device may create a practical barrier even when active-ingredient patents have expired. A competitor can avoid direct device infringement by using a different injector, cartridge, or administration format, but that may increase development cost and reduce patient convenience.
When does GONAL-F lose exclusivity?
GONAL-F does not have a single exclusivity date that determines all competitive risk. Its risk profile depends on separate legal and commercial events:
| Exclusivity layer |
Relevance |
| Biologic regulatory exclusivity |
Limits the timing of certain biosimilar approvals |
| Core molecule and production patents |
May have expired or become less commercially important |
| Formulation patents |
Can delay or complicate substitution |
| Pen and device patents |
Can protect the RFF REDIJECT presentation |
| Manufacturing know-how |
May deter technically difficult replication |
| Trademarks and branding |
Protect product identity, not the active ingredient |
| Clinical and physician familiarity |
Commercial protection after legal exclusivity weakens |
For a biologic, biosimilar entry does not operate like generic substitution for a small molecule. FDA must determine whether a proposed product is biosimilar, and interchangeability is a separate designation. Automatic pharmacy substitution depends on state law and interchangeability status.
What is the Orange Book status of GONAL-F RFF REDIJECT?
GONAL-F RFF REDIJECT should not be analyzed as a conventional Orange Book small-molecule product. The FDA’s Purple Book is the relevant reference for licensed biological products, biosimilars, and interchangeable biosimilars. The Orange Book generally does not provide the primary patent-listing framework for therapeutic biologics regulated under the Public Health Service Act (FDA, 2024a; FDA, 2024b).
This distinction has practical consequences:
- A conventional ANDA Paragraph IV challenge is not the normal pathway.
- A biosimilar sponsor uses the 351(k) pathway.
- Patent disputes may involve the Biologics Price Competition and Innovation Act patent-exchange process.
- The reference-product sponsor can assert formulation, process, device, and method-of-use patents.
- Market substitution depends on FDA interchangeability and state pharmacy law.
Which companies are challenging GONAL-F?
The most relevant competitive challenge is not an identified U.S. Paragraph IV generic challenge. It is competition from other gonadotropin brands and from follitropin alfa biosimilars in jurisdictions where they are approved.
Bemfola is an important European example. The European Medicines Agency authorized Bemfola as a biosimilar to GONAL-f, supporting the conclusion that follow-on competition is technically and regulatorily feasible in Europe (European Medicines Agency [EMA], 2014).
The U.S. market has not developed the same level of follitropin biosimilar competition. Entry would require analytical comparability, clinical development, manufacturing validation, FDA review, and resolution of patent and device issues.
What patent litigation and settlement risks affect GONAL-F?
No current product-specific litigation or settlement outcome should be inferred from the existence of competing fertility products. A conventional generic litigation pattern is not the expected framework for a biologic.
A future biosimilar dispute could involve:
- Patent-dance disclosures.
- Recombinant production processes.
- Cell-line or purification methods.
- Liquid formulation stability.
- Pen or cartridge architecture.
- Injection-device operation.
- Manufacturing controls.
- Treatment-method claims.
A settlement could establish a delayed launch date, a license, manufacturing restrictions, or geographic limits. Without a publicly reported settlement, no reliable launch date can be assigned to a hypothetical U.S. biosimilar.
What generic or biosimilar launch risks exist?
The near-term risk is more likely to arise from brand-to-brand competition and payer pressure than from automatic generic substitution. The medium-term risk is a U.S. biosimilar or follow-on product that offers a lower net price while matching the clinical profile of follitropin alfa.
U.S. launch scenarios
| Scenario |
Commercial effect |
| No U.S. biosimilar entry |
GONAL-F retains brand and formulary position, subject to competitor pressure |
| Noninterchangeable biosimilar entry |
Clinics may switch selected patients based on price |
| Interchangeable biosimilar entry |
Greater pharmacy-level substitution risk, subject to state law |
| Device-different biosimilar |
Lower price may be offset by training and operational friction |
| Formulary-exclusive competitor |
Rapid share loss in covered populations |
| Multiple entrants |
Greater net-price erosion and rebate competition |
The likely first impact of biosimilar entry would be lower net pricing and higher contracting costs. Unit volume could remain stable while revenue declines. A stronger volume shock would require payer-preferred placement, sufficient product supply, and a device that clinics and patients accept.
How strong is the GONAL-F patent estate?
The estate appears commercially meaningful but not equivalent to a broad, unexpired composition-of-matter monopoly. Its strength is more likely distributed across regulatory status, manufacturing know-how, product presentation, and market position.
| Patent-estate dimension |
Relative assessment |
| Core active ingredient |
Likely weaker for a mature recombinant biologic |
| Manufacturing process |
Potentially meaningful |
| Formulation |
Potentially meaningful if claims remain enforceable |
| Pen delivery system |
Potentially meaningful for direct device copying |
| Method of use |
Variable and protocol-dependent |
| Trade secrets |
Important but difficult to quantify |
| Trademark and brand |
Strong commercial recognition |
| Biosimilar barrier |
Moderate, depending on patent scope and FDA pathway |
The strongest practical barrier may be manufacturing and regulatory execution rather than a single blocking patent. Recombinant gonadotropins require controlled production, characterization, consistency testing, and validated supply. These requirements raise development costs and reduce the number of credible entrants.
What is the geographic coverage of GONAL-F and its competitors?
GONAL-F has broad international exposure through Merck KGaA’s global healthcare operations. Market conditions differ materially by jurisdiction.
United States
The U.S. market has high treatment prices, fragmented insurance coverage, specialty-pharmacy distribution, and growing employer-sponsored fertility benefits. Commercial success depends heavily on formulary contracting and clinic access.
Europe
European markets have stronger price controls and centralized or regional reimbursement decisions. Biosimilar competition is more established, and reference pricing can accelerate net-price erosion.
Emerging markets
Access is constrained by treatment affordability, fertility-clinic density, reimbursement, and cold-chain distribution. Volume growth may be possible, but net pricing is generally lower.
What is the investment outlook for GONAL-F RFF REDIJECT?
GONAL-F RFF REDIJECT is best viewed as a durable but mature specialty pharmaceutical asset. Its revenue base benefits from recurring fertility demand and established use, while its growth ceiling is constrained by competition and limited public evidence of standalone sales expansion.
The key financial indicators are:
- IVF cycle growth by geography.
- GONAL-F prescription and unit trends.
- Average gross-to-net discount.
- Formulary wins and losses.
- Employer-benefit adoption.
- Market share against Follistim and Menopur.
- European biosimilar penetration.
- U.S. biosimilar filings and approvals.
- Manufacturing capacity and supply continuity.
- Product-specific legal settlements.
Merck’s corporate reporting is sufficient to evaluate the strategic importance of the Healthcare and fertility businesses, but not to calculate a precise GONAL-F RFF REDIJECT valuation. Product-level revenue, profitability, and patent-adjusted cash flow require data not disclosed in the cited public materials.
Key Takeaways
- GONAL-F RFF REDIJECT is a mature recombinant follitropin alfa product marketed by EMD Serono and Merck KGaA.
- Its commercial advantages are brand recognition, established clinic use, dose flexibility, and a prefilled multidose pen.
- Merck does not disclose standalone product revenue, preventing a precise product-level financial forecast.
- The main competitors are Follistim AQ and Menopur, with European biosimilar competition from products such as Bemfola.
- GONAL-F should be evaluated through the biologic and Purple Book framework, not a conventional generic Orange Book and Paragraph IV framework.
- Future erosion is more likely to begin with payer contracting and net-price pressure than with immediate pharmacy substitution.
- Manufacturing complexity, formulation, device design, and regulatory requirements remain meaningful barriers to entry.
- The product’s financial profile is defensive and recurring but exposed to mature-brand pricing pressure and future biosimilar competition.
FAQs
Is GONAL-F RFF REDIJECT a biosimilar?
No. GONAL-F RFF REDIJECT is the branded recombinant follitropin alfa product. A biosimilar is a separately developed product shown to be highly similar to a licensed reference biologic.
Is GONAL-F automatically substituted at the pharmacy?
No. Automatic substitution depends on FDA interchangeability status and applicable state law. A biosimilar designation alone does not necessarily permit automatic substitution.
Does GONAL-F have an Orange Book patent expiration date?
Not in the same manner as a conventional small-molecule drug. Therapeutic biologics are primarily assessed through the Purple Book and biologics-specific regulatory and patent frameworks.
What is the main commercial difference between GONAL-F and Menopur?
GONAL-F provides recombinant FSH activity. Menopur is a menotropin product with FSH and LH activity, creating different protocol and physician-preference considerations.
Can a competitor copy the GONAL-F injection pen?
A competitor can develop a different delivery device, but direct copying may raise device, formulation, design, or patent issues. A noninfringing device may also reduce the commercial advantage of a follow-on product.
References
-
European Medicines Agency. (2014). Bemfola: EPAR - product information. https://www.ema.europa.eu/
-
Merck KGaA. (2024). Annual report 2023. https://www.merckgroup.com/
-
Merck KGaA. (2025). Annual report 2024. https://www.merckgroup.com/
-
U.S. Food and Drug Administration. (2023). GONAL-F RFF Redi-ject prescribing information. https://www.accessdata.fda.gov/
-
U.S. Food and Drug Administration. (2024a). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
-
U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
